000289215 001__ 289215
000289215 005__ 20250731112213.0
000289215 0247_ $$2doi$$a10.1002/cncr.35300
000289215 0247_ $$2pmid$$apmid:38564338
000289215 0247_ $$2ISSN$$a1934-662X
000289215 0247_ $$2ISSN$$a0008-543X
000289215 0247_ $$2ISSN$$a1045-7410
000289215 0247_ $$2ISSN$$a1097-0142
000289215 0247_ $$2ISSN$$a1934-6638
000289215 0247_ $$2altmetric$$aaltmetric:161516515
000289215 037__ $$aDKFZ-2024-00649
000289215 041__ $$aEnglish
000289215 082__ $$a610
000289215 1001_ $$00000-0003-3628-9056$$aSauer, Christina$$b0
000289215 245__ $$aElectronic health intervention to manage symptoms of immunotherapy in patients with cancer (SOFIA): Results from a randomized controlled pilot trial.
000289215 260__ $$aNew York, NY$$bWiley-Liss$$c2024
000289215 3367_ $$2DRIVER$$aarticle
000289215 3367_ $$2DataCite$$aOutput Types/Journal article
000289215 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719832637_5815
000289215 3367_ $$2BibTeX$$aARTICLE
000289215 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289215 3367_ $$00$$2EndNote$$aJournal Article
000289215 500__ $$a2024 Jul 15;130(14):2503-2514
000289215 520__ $$aFor patients receiving immune checkpoint inhibitors, early detection of immune-related adverse events (irAEs) is critical for one's safety. To this end, a smartphone app (SOFIA) was developed that featured the assessment of electronic patient-reported outcomes (ePROs) focusing on irAEs as well as a set of comprehensive supportive information. Its feasibility and preliminary efficacy were evaluated in a randomized controlled trial (RCT).Patients who received immune checkpoint inhibition therapy were randomly assigned to an intervention group (IG) or a control group (CG; care as usual). During the 12-week intervention period, IG patients used SOFIA to report twice weekly ePROs and receive cancer- and immunotherapy-relevant contents. Before a patient's next clinical visit, the physician in charge was given the ePRO reports. The primary objective was to test the feasibility of SOFIA. Furthermore, the preliminary efficacy of SOFIA for health-related quality of life (HRQOL), psychosocial outcomes, and medical data was examined. Clinical outcomes were assessed at baseline (T0), post-intervention (T1), and a 3-month follow-up (T2).Seventy-one patients were randomized to the IG (n = 34) or the CG (n = 37). SOFIA showed high feasibility and acceptance. At T1, patients in the IG reported significantly better HRQOL and role functioning and less depression, distress, and appetite loss. No significant differences were revealed regarding medical data, the utilization of supportive care services, or survival.SOFIA showed high feasibility and acceptance and improved HRQOL and psychosocial outcomes. These results suggest further evaluation of efficacy in a large-scale confirmatory multicenter RCT.
000289215 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000289215 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289215 650_7 $$2Other$$acancer
000289215 650_7 $$2Other$$aelectronic health (eHealth)
000289215 650_7 $$2Other$$aelectronic patient‐reported outcomes (ePROs)
000289215 650_7 $$2Other$$aimmunotherapy
000289215 650_7 $$2Other$$amobile health (mHealth)
000289215 650_7 $$2Other$$apsycho‐oncology
000289215 7001_ $$aZschäbitz, Stefanie$$b1
000289215 7001_ $$aKrauss, Jürgen$$b2
000289215 7001_ $$0P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aWalle, Thomas$$b3$$udkfz
000289215 7001_ $$0P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d$$aHaag, Georg Martin$$b4$$udkfz
000289215 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b5$$udkfz
000289215 7001_ $$aHiller, Kiriaki$$b6
000289215 7001_ $$aBugaj, Till Johannes$$b7
000289215 7001_ $$aFriederich, Hans-Christoph$$b8
000289215 7001_ $$aMaatouk, Imad$$b9
000289215 773__ $$0PERI:(DE-600)1479932-7$$a10.1002/cncr.35300$$gp. cncr.35300$$n14$$p2503-2514$$tCancer$$v130$$x0008-543X$$y2024
000289215 8564_ $$uhttps://inrepo02.dkfz.de/record/289215/files/Cancer%20-%202024%20-%20Sauer%20-%20Electronic%20health%20intervention%20to%20manage%20symptoms%20of%20immunotherapy%20in%20patients%20with%20cancer%20SOFIA%20.pdf
000289215 8564_ $$uhttps://inrepo02.dkfz.de/record/289215/files/Cancer%20-%202024%20-%20Sauer%20-%20Electronic%20health%20intervention%20to%20manage%20symptoms%20of%20immunotherapy%20in%20patients%20with%20cancer%20SOFIA%20.pdf?subformat=pdfa$$xpdfa
000289215 909CO $$ooai:inrepo02.dkfz.de:289215$$pVDB
000289215 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51635089578f68fc9efdb61e6a760b64$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289215 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289215 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289215 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000289215 9141_ $$y2024
000289215 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000289215 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000289215 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000289215 9201_ $$0I:(DE-He78)F230-20160331$$kF230$$lKKE Virotherapie$$x0
000289215 9201_ $$0I:(DE-He78)D490-20160331$$kD490$$lKKE Virotherapie$$x1
000289215 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x2
000289215 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000289215 980__ $$ajournal
000289215 980__ $$aVDB
000289215 980__ $$aI:(DE-He78)F230-20160331
000289215 980__ $$aI:(DE-He78)D490-20160331
000289215 980__ $$aI:(DE-He78)D120-20160331
000289215 980__ $$aI:(DE-He78)HD01-20160331
000289215 980__ $$aUNRESTRICTED